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 
Abstract—Comprehensive characterization and identification 
of cancer subtypes have a number of applications and implications 
in life science and cancer research. Technologies centered on the 
integration of omics data hold great promise in this endeavor. This 
paper proposed a multiplex network-based approach for 
integrative analysis of heterogeneous omics data. It represents a 
useful alternative network-based solution to the problem and a 
significant step forward to the methods in which each type of data 
is treated independently.  It has been tested on the identification of 
the subtypes of glioblastoma multiforme and breast invasive 
carcinoma from three omics data.  The results obtained have 
shown that it has achieved the performance comparable to state-
of-the-art techniques (Normalized Mutual Information > 0.8). In 
comparison to traditional systems biology tools, the proposed 
methodology has several significant advantages. It has the ability 
to correlate and integrate multiple data levels in a holistic manner 
which may be useful to facilitate our understanding of the 
pathogenesis of diseases and to capture the heterogeneity of 
biological processes and the complexity of phenotypes. 
 
Index Terms— Multiplex networks; omics data; cancer 
subtypes; data integration 
I. INTRODUCTION 
OMPREHENSIVE characterization and identification of 
cancer subtypes associated with distinct molecular profiles 
and differential clinical outcomes has significant applications 
and implications in life science and cancer research since it may 
 
 
lead, for example, to a better understanding of cancer evolution,  
new treatment insights, optimal patient stratification and the 
design of new, effective therapeutic strategies [1], [2]. A 
breakthrough reclassification of pancreatic cancer has been 
published in Nature recently and a total of 4 key subtypes, i.e. 
Squamous, Oancreatic Progenitor, ADEX, and Immunogenic, 
have been identified, providing a basis to offer new insights into 
personalized therapeutic treatments [1]. A new approach to the 
classification of patients for therapeutic purposes based on the 
recognition of intrinsic biological subtypes within the breast 
cancer spectrum was adopted by the 12th St Gallen International 
Breast Cancer Conference Expert Panel [3]. It has been 
highlighted that Luminal A patients generally only receive 
endocrine therapy, while for most patients with Triple negative, 
chemotherapy is required.  
However, due to its highly heterogeneous nature, different 
conclusions regarding the number of cancer subtypes in a tissue 
have been drawn depending on the types of data used and 
methodologies employed. In the context of the analysis of 
glioblastoma multiforme (GBM), for instance, Nigro et al. [4] 
identified two molecular subtypes with one group containing 
the most common copy number alteration, loss of chromosome 
10. By applying consensus hierarchical clustering to the 
analysis of expression data from 200 GBM and 2 normal brain 
samples assayed on three gene expression platforms, Verhaak 
et al. [5] classified GBM into 4 subgroups, i.e. Proneural, 
Neural, Classical and Mesenchymal. Using the same datasets, 
i.e. DNA methylation, mRNA expression and miRNA from 215 
patient samples with GBM and 105 samples with breast 
invasive carcinoma (BIC), Wang et al. [6] applied SNF and 
suggested 3 subtypes in GBM and 5 subtypes in BIC while 
Specicher and Pfeifer [7] identified 6 subgroups in GBM and 7 
in BIC with multiple kernel learning. 
Due to the ability to provide system-level measurements for 
nearly all biomolecules in the cell and opportunities to study 
biological systems at different levels, recent years have seen a 
growing trend toward the integration of diverse omics data for 
the identification of cancer subtypes. Recent examples include 
the identification of subtypes of pancreatic cancer associated 
with distinct histopathological characteristics and differential 
survival using a combination of the whole-genome and deep-
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exome sequencing with gene copy number analysis [1].  
While the growing availability of diverse omics data offers 
huge opportunities to generate a more thorough and 
comprehensive view of biological problems, mining such 
abundant information poses great challenges to research 
communities, requiring the development of advanced 
integrative analysis platform to capture the heterogeneity of 
biological processes and the complexity of phenotypes [6]. 
A. Current effort on omics data integration: a brief overview  
The recognized significance of data integration in the era of 
omics has triggered intense efforts across the global. For 
example, as a large-scale, collaborative effort led by the 
National Institute of Health, The Cancer Genome Atlas 
(TCGA) has collected massive, high quality information 
generated from various molecular levels for over 30 types of 
human cancer derived from about 10,000 cases of tumor and 
matching normal tissues samples. By enabling to map 
molecular alternation at multiple levels, TCGA provides a 
valuable resource to accelerate our understanding of the 
molecular basis of human cancers [8]. A number of EU projects 
focusing on integrative analysis of diverse omics data have been 
funded under EU FP7-Health programme. Examples include 
the STATegra project (http://www.stategra.eu/), which 
involves 11 partners from different countries. Since 2007, the 
European Commission has actively participated several 
international large scale omics research initiatives including 
International Cancer Genome Consortium (https://icgc.org/) 
and International Human Epigenome Consortium (http://ihec-
epigenomes.org/). Gomez-Cabrero et al. [9] characterized 
current efforts on data integration in the life science. A recent 
review on the emerging approaches for omics data integration 
to uncover genotype-phenotype interactions was provided by 
Ritchie et al. [10]. 
Over the past decades, a wide range of computational 
approaches have been proposed and developed. Using a model-
based integration strategy, Akavia et al. [11] developed a 
computational framework that integrates chromosomal copy 
number and gene expression data for detecting aberrations that 
promote cancer progression. Relying on the use of kernel-based 
statistical learning methods, Lanckriet et al [12] introduced a 
computational framework for genomic data fusion, in which 
each type of data is represented via a kernel function that 
defines similarities between pairs of entities, such as genes or 
proteins. It has been shown that kernel functions derived from 
different types of omics data can be combined in a 
straightforward fashion. Kim et al. [13] introduced a graph-
based approach for predicting clinical outcomes in brain cancer 
and ovarian cancer by integrating multi-omics data as a 
transformation-based integration. A graph-based semi-
supervised learning was used as a classification algorithm. 
Integration of multi-level genomic data sources was achieved 
by finding an optimum value of the linear combination 
coefficient for the individual graphs derived from each type of 
data. Using a joint latent variable model for integrative 
clustering, the iCluster method [14] seeks to find a single 
common clustering structure for all omics data involved. The 
number of clusters needs to be estimated by heuristic 
approaches. 
More recently, Wang et al. [6] introduced a novel network-
based approach, i.e. Similarity Network Fusion (SNF), for 
aggregating data types on a genomic scale. It consists of two 
main steps: constructing a patient-similarity network for each 
available omics data and fusing all networks into a single 
similarity network with a nonlinear combination method to 
represent the full spectrum of underlying data. The approach 
has been applied to combine 3 omics data, i.e. mRNA 
expression, DNA methylationa, and miRNA expression for five 
cancer datasets including glioblastoma multiforme (GBM). It 
has been shown that SNF substantially outperforms single data 
type analysis and established integrative approaches. 
B. The objectives in this study 
In this study we proposed an alternative network-based data 
integration strategy, i.e., a multiplex network-based integrative 
approach for exploring large volumes of multivariate patient 
data based on the extension of our previous analysis [15]. 
Similar to SNF, for each type of data, a patient-similarity 
network is generated. After that, a multiplex network is formed 
by introducing a coupling strength that links each node in a 
network slice and its counterpart in each of the other network 
slices. To demonstrate its performance, the proposed method is 
applied to identify the subtypes of GBM and BIC. An empirical 
study of the impact of the selection of learning parameters on 
the performance is carried out.  
The rest of paper is organized as follows. Section II briefly 
describes the methodology, datasets under study, and 
evaluation metrics used to assess the significance of results. The 
formation of multiplex networks and its implementation are 
provided. The results and discussions are presented in Section 
III. The conclusions, together with the discussion of limitations 
and future research, are given in Section IV. 
II. METHODOLOGY 
Inspired by the recent work published by Mucha et al. [16], 
a multiplex network(MN)-based clustering approach is 
proposed to explore large volumes of multivariate patient data. 
As illustrated in Fig. 1, for each given dataset, a network will 
be constructed, in which each node corresponds to a patient and 
each edge represents the similarity between a pair of patients 
derived from the given dataset. The whole multiplex networks 
can be represented using a 3rd-order tensor 𝐴 = (𝐴𝑖𝑗𝑠)𝑛×𝑛×𝑘 , 
where n is the number of patients and k is the number of datasets 
under consideration. Each element 𝐴𝑖𝑗𝑠  is the non-negative 
value representing the weight associated with the link between 
a pair of patients in the network derived from dataset s. 
A. Cluster detection across multiscale networks 
Unlike the traditional approach, in which each network is 
treated independently, we propose a flexible framework for 
integrative clustering analysis of heterogeneous data based on 
the adaptation of the generalized modularity proposed by 
Mucha et al. [16]. The generalized modularity shown in (1) will 
be used as an objective function to optimize partitions across 
networks. As shown in (1), there are two parts in the 
representation, i.e. the first part is responsible for the 
modularity derived from each network [17] and the second part 
is to enforce a consensus in terms of cluster assignments. The 
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3 
optimal solution will be achieved when the same node (patient) 
across all the networks is assigned to the same cluster. The 
significance of the second part is determined by the coupling 
strength, ω, representing the relationship between two sets of 
datasets. When ω = 0, the optimal partition is achieved from 
separate optimisation in each network. As ω is increased, the 
optimisation will gradually force the cluster assignment of a 
node to remain in the same partition across networks. This 
becomes more evident when similar patterns are observed 
across datasets. Such a feature lends itself naturally to providing 
a flexible framework for integrative clustering analysis of 
multiple heterogeneous data.  
𝑄𝑚 =
1
2𝜇
∑ [(𝐴𝑖j𝑠 − 𝛾𝑠
𝑘𝑖𝑠𝑘𝑗𝑠
2𝑚𝑠
) 𝛿(𝑐𝑖𝑠 , 𝑐𝑗𝑠)]
𝑖𝑗𝑠
+
1
2𝜇
∑𝜔𝑖𝑠𝑟𝛿(𝑐𝑖𝑠 , 𝑐𝑖𝑟)
𝑖𝑠𝑟

(1) 
where Aijs, kis, and ms represent the adjacency matrix, the 
degree of node i, and the total number of links in network s 
respectively. 𝜔𝑖𝑠𝑟  stands for the strength between networks 
constructed from datasets s and r for node i and 𝜇 =
 
1
2
∑ (∑ 𝐴𝑖𝑗𝑠 + ∑ 𝜔𝑗𝑠𝑟𝑟𝑖 )𝑗𝑠 . For each network s,  𝛾𝑠  is the 
resolution parameter used to examine cluster structure at 
multiple scales and 𝑐𝑖𝑠 represents cluster assignment of node i 
in network s. For simplicity, the inter-slice couplings between 
network s and r, 𝜔𝑖𝑠𝑟 ,  take binary values {0, ω} indicating 
absence/presence of the inter-slice links. 𝛿(𝑐𝑖𝑠 , 𝑐𝑗𝑟) is the 
Kronecker delta function which is equal to 1 when two nodes 
in a network or a node from two slices are assigned to the same 
community. 
 
B. Implementation 
The implementation was based on the generalized Louvain 
MATLAB code [18]. It implements a Louvain-like greedy 
community detection method that is based on modularity 
optimization [19]. As illustrated in Fig. 2, the algorithm consists 
of two main stages that are repeated iteratively. Starting with 
assigning a different cluster to each node in a network, the first 
phase is repeated by moving a node from its community and 
placing it in the community of its neighbours at a time to 
optimize the specified quality function until no further 
improvement can be achieved. The second phase is to build a 
new network whose nodes represent the communities found 
during the first stage. 
 
 
Fig. 2 An illustration of a Louvain-like greedy community detection method 
The beauty of the generalized Louvain approach [18] is that 
it works directly with the modularity matrix and thus can be 
used with any quality function specified in terms of a 
modularity matrix. The corresponding multislice modularity 
matrix associated with the quality function defined in Eq.(1) 
can then be derived as illustrated in Fig. 3. In this study, we 
considered the type of interlayer connectivity as categorical, i.e. 
the interslice couplings connect an individual (patient in this 
study) in a network to himself or herself in each of remain 
networks as shown Fig. 1. The reader is referred to [18] for a 
detailed description of its implementation. 
 
[
 
 
 
 
 
 
 
 (
𝐵001 ⋯ 𝐵0𝑛1
⋮ ⋱ ⋮
𝐵𝑛01 ⋯ 𝐵𝑛𝑛1
) 𝜔1𝑠 𝜔1𝑟
𝜔1𝑠 (
𝐵00𝑠 ⋯ 𝐵0𝑛𝑠
⋮ ⋱ ⋮
𝐵𝑛0𝑠 ⋯ 𝐵𝑛𝑛𝑠
) 𝜔𝑠𝑟
𝜔1𝑟 𝜔𝑠𝑟 (
𝐵00𝑟 ⋯ 𝐵0𝑛𝑟
⋮ ⋱ ⋮
𝐵𝑛0𝑟 ⋯ 𝐵𝑛𝑛𝑟
)
]
 
 
 
 
 
 
 
 
 
Fig. 3 An illustration of a modularity matrix for categorical multislice networks. 
𝐵𝑖𝑗𝑠 = 𝐴𝑖j𝑠 − 𝛾𝑠
𝑘𝑖𝑠𝑘𝑗𝑠
2𝑚𝑠
 where Aijs is the adjacency matrix for slice s. ωsr represents 
the interslice coupling between slices s and r. 
Fig. 1. A flexible, multiplex network-based framework for integrative 
clustering analysis. s, k, and r represent similarity networks constructed from 
the corresponding datasets. Each node in the networks is associated with a 
patient and each edge represents the similarity between a pair of patients 
derived from the given dataset. ωisr represents the coupling strength between 
two slices, i.e. s and r, for node i. 
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C. Datasets under study  
Three types of omics data available from the TCGA website 
preprocessed by Wang et al. [6] were used: mRNA expression, 
miRNA expression, and DNA methylation. The proposed 
method has been applied to the analysis of two cancer types, i.e. 
GBM with 215 samples in which 134 were male and 81 female 
and BIC with 104 female samples. The platforms used to 
generate the data  and the details of data preprocessing 
including g normalization can be found in [6]  
The formation of multiplex networks was based on patient-
wise similarity matrices published by Wang et al. [6]. They 
were computed with a scaled exponential similarity kernel [6] 
as defined below. 
𝑃(𝑖, 𝑗) = 𝑒𝑥𝑝 {−
𝑑2(i, j)
𝜇𝜖𝑖,𝑗
} (2) 
where µ is a hyperparameter and 𝜖𝑖,𝑗 is used to avoid scaling 
problems. 𝑃(𝑖, 𝑗) represents similarity between two patients, i 
and j, and 𝑑(𝑖, 𝑗) is a distance function used to calculate the 
patient-wise distance for a given dataset. After that, a K nearest 
neighbours (KNN)-based method is used to estimate local 
affinity. The similarities between non-neighbouring patients are 
set to zero as illustrated below. 
𝑆(𝑖, 𝑗) = {
𝑃(𝑖, 𝑗)
∑ 𝑃(𝑖,𝑚)𝑚∈𝑁𝑖
              𝑗 ∈ 𝑁𝑖
  0                              𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
 (3) 
where 𝑆(𝑖, 𝑗) represents the normalized similarity based on  
the  K most similar patients (Ni) for each patient. 
D. Evaluation metrics 
To assess the significance of differences between GBM 
subtypes identified in terms of their survival profiles, the log 
rank test of the Cox regression model [21] was used. It is a 
nonparametric hypothesis test. The null hypothesis is two 
groups have identical survival functions. The p value estimated 
indicates how likely the observed differential survival profiles 
occur by chance. The Kaplan-Meier estimator [22] is utilized to 
estimate the survival function, ?̂?(𝑡), i.e. the probability that a 
patient survives longer than time t.  
In order to study whether certain type of proteins/genes are 
enriched in a GBM subtype, we adopted hypergeometric 
distribution function defined as follows. 
𝑝 = 1 − ∑ (
𝐾
𝑖
) (
𝑁 − 𝐾
𝑛 − 𝑖
) (
𝑁
𝑛
)⁄
𝑘−1
𝑖=1
 (4) 
where N and K represent the sizes of population and the 
sample (subtype in our case) drawn from the population without 
replacement respectively, and n and k stand for the numbers of 
certain types of proteins/genes in the population and the sample 
respectively. The estimated p represents the probability of 
observing at least k members from a sample drawn from a 
population of size N having n members in total without 
replacement by chance. 
III. RESULTS AND DISCUSSION 
E. GBM subtypes derived from clustering analysis of the 
multiplex networks 
Two learning parameters need to be set in the clustering 
algorithm used in the study, i.e. γ (resolution parameter) and ω 
(coupling strength). Unless indicated otherwise, γ is set to 0.2 
throughout this study. As expected, separate subtypes were 
generated with ω = 0 for each network with each patient was 
assigned to 3 separate subtypes. A total of 19 subtypes were 
produced when ω is set to zero: 6 for mRNA expression data, 5 
for DNA methylation and 8 for miRNA expression. As ω was 
introduced, subtypes merged across networks quickly. This not 
only reduced the total number of subtypes but more importantly 
patients were gradually assigned to one subtype. When ω was 
increased to 0.3, a total of 3 subtypes were derived: 63 in G1, 23 
in G2, and 131 in G3 as shown in Table I. 
TABLE I THE CHARACTERISTICS OF 3 GBM SUBTYPES IDENTIFIED 
Subtypes dentified G1 G2 G3 
Number of patients  
61 
(M: 38, F:23) 
23 
(M:11, F:12) 
131 
(M: 85, F:46) 
Average age 
(years) 
52.85 40.61 61.61 
Average survival 
time (days) 
657.56 1140.65 467.96 
 
As illustrated in Fig. 4, similarity networks derived from 3 
datasets exhibit very different patterns. DNA methylation 
appears to support connectivity in the medium sized cluster, i.e. 
Subtype G1 (Fig. 4(b)). While patterns shown in Fig.4(a) 
suggest relatively strong intercluster mRNA expression-based 
similarity, it would be hard to derive any convincing conclusion 
from the miRNA-based similarity network (Fig. 4(c)). 
 
 
Fig. 4. Patient similarities in each subtype for each of the dataset: (a) mRNA 
expression data; (b) DNA methylation data; (c) miRNA expression data. The 
graph was drawn using MATLAB code released by Wang et al. [6]. The 
similarity value of each pair correlates with color intensity, black with the 
similarity level equal to zero. 
F. Correlation with Clinical Variables 
We first investigated the correlation between GBM 
subtypes identified and age, one of the most important 
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prognostic factor in GBM [23]. A statistically significant 
difference in terms of the average age was observed across 3 
subtypes (ANOVA test, p < 0.0001) with the smallest patient 
cluster (Subtype G2) being closely associated with younger 
patients (median age 34 years). Two post-hoc tests, namely 
Bonferroni’s method and Tukey's Honestly Significant 
Difference (HSD) test, indicate that all pairs of subtype mean 
ages are significantly different (p < 0.05). 
Next we studied survival profiles associated with each 
subtype, i.e. the number of days to the last follow-up where4 
available [6]. As depicted in Fig. 5, survival times are 
significantly different among three GBM subtypes with patients 
in Subtype G2 having a more favorable prognosis (Average 
survival time 1140.65 days). The overall Cox log rank p value 
for 3 subtypes is 0.000251. 
 
Fig. 5. Kaplan-Meier survival curves for three GBM subtypes as identified 
(overall Cox log rank p-value for 3 subtypes is 0.000251). 
Finally, we examined patient response to treatment with 
temozolomide (TMZ), a chemotherapy drug used to treat 
certain types of brain tumors including GBM. As illustrated in 
Fig. 6, patients with GBM in Subtypes G1 and G3 had a 
significantly increased survival time (Cox log-rank test, p < 
0.005), whereas for patients associated with Subtype G2, no 
significant difference in survival time was observed. 
Fig 6. Survival analysis of GBM patients for treatments with TMZ in Subtype 
G1. Patients associated with Subtype G1 had a significantly increased survival 
time (Cox log-rank test, p < 0.005). Similar observation can be made when 
examining patients in Subtype G3. 
G. Comparisons with state-of-the-art and established 
subtypes 
We first compared our results with the study by Wang et al. 
[6] published in Nature Method in 2014. As summarized in 
Table II, a comparable result was obtained in our study. Patients 
assigned to Clusters 1, 2 and 3 by SNF are highly enriched in 
Subtypes G3, G1, and G2 respectively (hypergeometric test, p 
< 0.0001). The value of Normalized Mutual Information (NMI) 
between subtypes identified and cluster labels obtained by SNF 
(0.80) suggests a high concordance between two results. 
TABLE II COMPARISONS WITH CLUSTERS IDENTIFIED USING SNF [6] 
Subtypes 
identified 
Clusters identified by SNF 
Cluster 1 Cluster 2 Cluster 3 
G1 1 59 1 
G2 2 0 21 
G3 126 5 0 
 
The comparison with 4 established subtypes, i.e. Classical, 
Mesenchymal, Neural and Proneural, determined primarily by 
expression data [5] is summarized in Table III. Subtypes G1 and 
G2 are strongly enriched for the mesenchymal GBM 
(hypergeometric test, p < 10-12) and the proneural type 
(hypergeometric test, p < 10-13), respectively. Subtype G3 
contains samples that belong to all 4 types of GBM, however, 
both classical and neural samples are over-represented in this 
subtype (hypergeometric test, p < 0.01). Given that 4 
established subtypes were mainly determined based on the 
analysis of their expression data, the distribution of other omics 
data over these 4 subtypes deserves further investigation. 
TABLE III COMPARISONS WITH 4 ESTABLISHED GBM SUBTYPES  
Subtypes 
identified 
4 established subtypes [5] 
Classical Mesenchymal Neural Proneural 
G1 7 34 7 9 
G2 1 0 1 20 
G3 40 20 20 23 
 
 A recent study by Sturm et al. [24] identified an epigenetic 
subgroup of GBM with a distinct global methylation pattern 
characterized by a somatic mutation in IDH1. Interestingly we 
found that out of 15 patients with an IDH1 mutation, 13 belong 
to the Subtype 2 identified in this study. 
H. Applying the MN approach to the analysis of breast cancer 
To further evaluate the MN performance, we applied it to the 
analysis of BIC. The optimal number of subtypes identified is 
3, which is in agreement with the numbers suggested by Wang 
et al. [6] based on the analysis of similarity networks using the 
two heuristics, i.e. eigengaps and rotation cost. 
The characteristics of 3 BIC subtypes are shown in Table IV. 
Both patients in Subtypes B1 and B2 were diagnosed with 
infiltrating ductal carcinoma, which is the most common type of 
breast cancer. All 7 patients diagnosed with infiltrating lobular 
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carcinoma were found in the Subtype B1. However, no 
significant difference between ductal and lobular carcinomas 
was observed in terms of their survival profiles (Cox log-rank 
test, p > 0.1). 
TABLE IV THE CHARACTERISTICS OF 3 BIC SUBTYPES IDENTIFIED 
BIC Subtypes B1 B2 B3 
Number of patients 46 30 29 
Average age (years) 56.43 51.94 60.38 
Average survival 
time (days) 
1310.98 939.17 733.41 
Infiltrating Ductal 
Carcinoma 
37 29 26 
Infiltrating Lobular 
Carcinoma 
7 0 0 
ER+ 45 8 27 
 PR+ 45 5 20 
Chemotherapy 21 23 16 
Hormone therapy 21 4 14 
*ER+: Estrogen-receptor-positive; PR+: Progesterone-receptor-positive;  
 
There is marginally significant difference between the 3 
subtypes in terms of their ages at initial pathologic diagnosis 
(Kruskal-Wallis test, p = 0.05) with the subtype B3 associated 
with elderly patients (mean rank: 61.55).  
Turning to survival analysis, statistically significant 
difference in survival profiles between the subtypes were 
observed as depicted in Fig. 7 (Cox log-rank test, p < 0.01) with 
the largest subgroup (Subtype B1), in which 45 out of 46 
patients are both estrogen receptor (ER) positive and 
progesterone receptor (PR) positive, having a more favorable 
prognosis (Average survival time 1310.98 days). This is 
consistent with the clinic observation that patients with both 
ER+ and PR+ have better clinical outcomes, which is supported 
by the recent study published in Nature [25]. 
According to latest 5-year survival rates for women of 
different ages with breast cancer in England from Cancer 
Research UK (https://www.breasthealthuk.com/about-breast-
cancer/breast-cancer-survival-rates), women aged between 40 
and 70 have better outcomes than younger women and women 
older than 70, especially for patients over 80 years of age whose 
survival rate is about 68.5%. However, no significant difference 
was found in survival between age groups across all three 
subgroups (Cox log-rank test, p > 0.1). This could be partially 
attributed to the lack of sufficient number of patients in some 
age groups. For example, only two subtype B1 patients belong 
to the groups younger than 40 and over 80, respectively. 
A variety of drugs have been used to treat breast cancer. 
Among 76 patients which have drug information available, 
about 35 drugs have been used with cyclophosphamide being the 
commonly used one. While there are 11 drugs found to be used 
to treat all 3 subtype patients, some drugs are used to treat a 
particular subtype of patients. For example, drugs bevacizumab, 
clodronic acid, doxorubicin, toremifene, gemcitabine, 
methotrexate, and Taxane are used only to treat patients 
associated with Subtype B2. 
 
Fig. 7. Kaplan-Meier survival curves for three BIC subtypes as identified (overall 
Cox log rank p-value for 3 subtypes is less than 0.01). 
Finally, we compared our results with state-of-the-art and 
known subtypes. The comparison with the 5 subtypes identified 
by Wang et al. [6] is shown in Table V. A high value of NMI 
(0.803) was obtained, indicating a high degree of concordance 
between two sets of clustering. 
TABLE V COMPARISONS BIC SUBTYPES WITH CLUSTERS IDENTIFIED USING 
SNF [6] 
Clusters 
identified by 
SNF 
BIC Subtypes identified 
B1 B2 B3 
Cluster 1 0 7 0 
Cluster 2 0 22 0 
Cluster 3 0 0 10 
Cluster 4 46 1 1 
Cluster 5 0 0 18 
TABLE VI COMPARISONS BIC SUBTYPES WITH 4 WELL KNOWN MOLECULAR 
SUBTYPES [25] 
MOLECULAR 
SUBTYPES 
BIC Subtypes identified 
B1 B2 B3 
Luminal A 40 2 9 
Luminal B 3 0 15 
Basal-like 0 23 0 
HER2-enriched 2 5 5 
 
It has been shown that each of four main breast cancers, i.e., 
Luminal A, Luminal B, Basal-like, and HER2-enriched exhibits 
significant molecular heterogeneity as highlighted in the study 
reported in [26]. Comparing with its results (Table VI), we 
found that luminal A cancers which are the most likely to retain 
activity of two major tumor suppressors, i.e. PB1 and TP53, are 
highly enriched in Subtype B1 that have the best  prognosis as 
shown Fig. 7 (hypergeometric test, p < 0.0001).  Luminal B 
tumours in which the TP53 pathway is often inactivated are 
highly over-represented in the more aggressive Subtype B3 
patients. All 23 basal-like breast cancers which are more likely 
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to lose the function of TP53, RB1 and BRCA1 are found in the 
group of patients in Subtype B2, over 70% of which are triple 
negative, i.e. negative for ER, PR and HER2. 
I. The impact of learning parameters  
The construction of patient-wise similarity networks was 
based on the approach introduced in [6] in which the following 
two parameters were used: (1) k, the number of neighbours 
which is used to measure local affinity with K nearest 
neighbours (KNN); and µ, a hyperparameter used to determine 
similarity kernel. It was recommended setting µ in the range of 
[0.3, 0.8] and k less than 30. In this section we first examined 
the impact of these parameters on the performance. Without 
losing generality, the BIC dataset was used in this analysis. We 
assessed the performance based on the comparison with the 
SNF approach [6]. 
As shown in Table VII, the high level of concordance was 
achieved when k is set to a range between 7 and 10 which is 
consistent with Wang et al. study [6]. They suggested to set k 
equal to 𝑁/10  approximately (N is the number of subjects) 
where the knowledge of the number of clusters is not available. 
The performance is significantly deteriorated when k greater 
than 15, especially when k = 20, the model essentially fails to 
differentiate patients with all the patients grouped together. 
TABLE VII THE IMPACT OF THE SELECTION OF THE NUMBER OF NEIGHBOURS 
(K) ON THE ANALYSIS  
Number of 
neighbours (k) 
5 7 10 12 15 20 
The number of 
subtypes identified 
5 3 3 2 2 1 
NMI 0.667 0.812 0.803 0.618 0.701 0.000 
 
The impact of the selection of the hyperparameter, i.e. µ, is 
depicted in Table VIII. The model appears to be sensitive to the 
variation of µ with the best performance was obtained when µ 
is set to the range between 0.45 and 0.50. 
TABLE VIII THE IMPACT OF THE SELECTION OF THE HYPERPARAMETER, µ, ON 
THE ANALYSIS 
µ 0.40 0.45 0.50 0.55 0.60 0.70 
The number of 
subtypes identified 
8 4 3 2 2 1 
NMI 0.671 0.853 0.803 0.538 0.487 0.000 
 
There are two learning parameters required for the multiplex 
network clustering algorithm used in our study, i.e. γ and ω. As 
expected the value of a resolution parameter γ has significant 
impact on the number of subtypes identified. The best 
performance was achieved when γ is set to the range of [0.2, 
0.3]. Turning to the parameter ω representing to the couple 
strength between networks, we found that the system is robust 
to the selection of ω when γ is set to 0.2 and ω is greater than 
0.1. 
IV. CONCLUSIONS 
It has been well recognized that comprehensive 
characterization and identification of cancer subtypes have a 
number of applications and implications in life science, for 
example, leading to a better understanding of heterogeneity of 
phenotypes and cellular organization at different levels.  
Technologies centered on the integration of omics data hold 
great promise in this endeavor. This paper proposed a multiplex 
networks-based approach for integrative analysis of 
heterogeneous omics data. It represents a useful alternative 
network-based solution and a significant step forward to the 
methods already in use in which each type of data is treated 
independently.  It has been tested on the identification of GBM 
and BIC subtypes from three omics data, i.e. RNA expression, 
DNA methylation and miRNA expression. Results obtained 
have shown that a high level of concordance (NMI > 0.8) has 
been achieved in comparisons to state-of-the-art techniques. The 
proposed methodology has several useful features. For example, 
it allows researchers to compare the biological/clinical patterns 
observed in a patient against data from large numbers of other 
patients which may be from different ethnic groups and subject 
to different environmental and epigenetic influences. It provides 
a flexible platform to integrate different types of patient data, 
potentially from multiple sources, allowing discovering 
complex disease patterns with multiple facets. The proposed 
platform has the ability to correlate and integrate multiple data 
levels in a holistic manner to facilitate our understanding of the 
pathogenesis of disease. 
This paper also provides an empirical analysis of the impact 
of the selection of some learning parameters on the analysis. It 
suggests that in general the results are not critically sensitive to 
the selection of k used to measure local affinity for a given 
patient. However, it appears that the system is quite sensitive to 
the variation of hyperparameter, i.e. µ. As expected, the values 
of the resolution parameter γ and the couple strength ω have 
impact on the number of subtypes identified although it appears 
to be robust to the selection of ω when γ = 0.2 and ω > 0.1 in 
the analysis of BIC data.  However, there is no standard way to 
determine the optimal value of these learning parameters in 
advance. Currently the determination of the learning parameters 
including resolution and coupling strength was based on trial 
and error. How to automatically determine the best combination 
of learning parameters would be part of future research. 
Another future direction concerns the way in which the 
coupling strength is determined. For simplicity, in this paper we 
have specified the parameter to an equal value between 
networks. Clearly, a more desirable solution is to assign the 
strength between networks in the way which could reflect the 
characteristics of datasets under investigation.  
The proposed method was applied to the identification of 
subtypes of GBM and BIC. We are extending our analysis to 
the study of other human cancers such as pancreatic cancer and 
colon adenocarcinoma.  
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